文献速递膀胱癌与上尿路尿路上皮癌

肿瘤出芽在肌层浸润性膀胱癌中的预后价值

Tumor Budding: Prognostic Value in Muscle-invasive Bladder Cancer.
PubMed 文献 · Urology · 2019-04-12

回顾性分析106例接受根治性膀胱切除术的肌层浸润性膀胱癌患者,用细胞角蛋白AE1/AE3免疫染色以热点法计数肿瘤出芽。ROC曲线确定14个出芽为截断值,低级别出芽组中位生存69.5个月,高级别出芽组18.5个月(P=.003)。多因素分析显示肿瘤出芽是癌症特异性死亡的独立预测因素。

要点

  • 肿瘤出芽定义为肿瘤浸润前沿孤立或少于5个细胞的小簇状肿瘤细胞。
  • 以14个出芽为截断值,高级别出芽组中位生存18.5个月,低级别组69.5个月(P=.003)。
  • 出芽数超过14个者死亡风险为2.27倍(95%CI 1.19-4.34,P=.013),每增加1个出芽死亡风险上升2%。

核心结论

  • 肿瘤出芽是肌层浸润性膀胱癌癌症特异性死亡的独立预测因素,截断值为14个出芽。

研究设计与样本

  • 回顾性研究纳入106例接受根治性膀胱切除术的肌层浸润性膀胱癌患者,采用细胞角蛋白AE1/AE3免疫染色以热点法识别和计数肿瘤出芽。

主要发现

  • 平均随访时间47±46.45个月,平均肿瘤出芽计数32.3±25.9个。
  • ROC曲线确定14个出芽为截断值,低级别出芽组(≤14个)中位生存69.5个月,高级别出芽组(>14个)中位生存18.5个月(P=.003)。
  • 多因素分析中,与死亡相关的独立预测变量为年龄、肿瘤出芽和TNM分期。
  • 出芽数超过14个者死亡风险为2.27倍(95%CI 1.19-4.34,P=.013),且死亡风险随出芽数增加以每个出芽2%的速率逐渐上升。

关键数值与推荐

  • 肿瘤出芽定义为肿瘤浸润前沿孤立或少于5个细胞的小簇状肿瘤细胞。
  • 以14个出芽为截断值区分低级别出芽(≤14个)与高级别出芽(>14个)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJETIVES: To assess if "tumor budding" (TB) behaves as a poor prognostic factor in muscle-invasive bladder carcinoma (MIBC). TB is the presence of tumor cells isolated or in small groups of fewer than 5 cells located at the tumor invasion front. MATERIAL AND METHODS: Retrospective study of 106 patients with MIBC who underwent radical cystectomy. A cytokeratin AE1/AE3 immunostaining was applied to identify and quantify TB by the "hot-spot" method. The variables evaluated were: age, gender, Tumour, Node, Metastasis Classification (TNM) stage, associated Carcinoma in situ, differentiation degree, tumor size, tumor location, lymphatic, venous or perineural invasion, p53, Ki67, molecular subtype (basal/luminal) and chemotherapy. Main variables were overall and cancer-specific survival. RESULTS: The mean follow-up time was 47 ± 46.45 months. The mean TB count was 32.3 ± 25.9 "buds." The ROC curve established 14 "buds" as the cut-off point: the median survival rate for the "low-grade TB" group (≤14 "buds") was 69.5 months, and for the "high-grade TB" group (>14 "buds") was 18.5 months (P= .003). In the multivariate analysis, independent predictive variables regarding mortality were: age, TB, and TNM stage. Patients with more than 14 "buds" had 2.27 times more risk of mortality, 95%CI:1.19-4.34, P = .013. In addition, the risk of mortality rises progressively as the number of "buds" increases, at a rate of 2% per "bud." CONCLUSION: According to our results, TB becomes an independent predictor factor for cancer-specific mortality in MIBC, with a cut-off point of 14 "buds."

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Lorenzo Soriano L, Ordaz Jurado G, Pontones Moreno JL, et al. Tumor Budding: Prognostic Value in Muscle-invasive Bladder Cancer. Urology. 2019. PMID: 30986485. doi:10.1016/j.urology.2019.04.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。